StocktoriaTranscode Therapeutics, Inc. RNAZ
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-1.34
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$28.0M | -$15.7M | -$19.4M | -$18.6M | -$6.2M |
| Net income | -$34.7M | -$16.8M | -$18.5M | -$17.6M | -$6.8M |
| Operating cash flow | -$19.5M | -$13.3M | -$18.1M | -$15.8M | -$5.3M |
| Free cash flow | -$19.5M | -$13.4M | -$18.1M | -$15.9M | -$5.5M |
| Total assets | $162.4M | $7.3M | $5.2M | $7.6M | $22.9M |
| Total liabilities | $10.5M | $9.3M | $3.5M | $4.3M | $2.5M |
| Shareholders' equity | $10.3M | -$2.0M | $1.6M | $3.2M | $20.4M |
| Ratios | |||||
| Return on assets | -21.3% | -229.7% | -358.7% | -231.5% | -29.8% |
| Return on equity | -335.4% | 830.0% | -1130.3% | -542.0% | -33.5% |
| Current ratio | 6.29 | 2.56 | 1.28 | 1.70 | 8.97 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1.34 (distress)
- Working capital / assets 0.114
- Retained earnings / assets -0.603
- EBIT / assets -0.172
- Equity / liabilities 0.983
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001829635 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.